Kidney disease and hemodialysis: identification of blood biomarkers to detect heart failure and kidney failure by Dudel Mayer, Barbara Letícia et al.
 
 
44  Kidney disease and hemodialysis: identification of blood biomarkers to detect heart failure 
and kidney failure 
 
















Kidney disease and hemodialysis: identification of blood biomarkers 
to detect heart failure and kidney failure 
Enfermedad renal y hemodiálisis: identificación de biomarcadores sanguíneos 
para detectar insuficiencia cardíaca e insuficiencia renal 
 
Barbara Letícia Dudel Mayer1,    Pollyana Thays Lameira da Costa1,    Maria Elena Echevarría-Guanilo1, 
Silvana Silveira Kempfer1,     Kleber Maciel da Silva Pieri2 
1Graduate Nursing Program, Department of Nursing, Federal University of Santa Catarina, Florianópolis, Brazil. 
2Clinical Analysis Laboratory, University Hospital, Federal University of Santa Catarina, Florianópolis, Brazil. 
 
Abstract 
Introduction: Chronic hemodialysis aims to replace renal function and provides an extension of life expectancy, however, complications 
do occur and they can be serious even fatal. Knowing the complications can enable a better prognostic evaluation and use of an 
intervention approach. These can be identified when performing anamnesis and physical examination, as well as, with greater 
precision, by means of renal and cardiac biomarkers and imaging tests. 
Objectives: to identify valid blood biomarkers to detect heart failure and kidney failure associated with kidney disease and 
hemodialysis. 
Methods: systematic literature review conducted in August 2018 in the following: Web Of Science, PubMed, Scopus, Cinahal, 
Cochrane, Science Direct and Lilacs. The guiding question was: “What are the blood biomarkers used to detect heart failure and 
kidney failure?” A total of 537 publications were found, 94 of these appeared more than once, 383 were excluded after reading titles 
and abstracts, 32 were excluded after reading the full texts, and 10 were excluded in the quantitative and qualitative synthesis. 
Results: 18 papers compose the final sample and report laboratory and imaging tests, instruments to assess the risk of kidney and 
heart failure, and also clinical management of the progression of kidney and heart failure. All the studies correlated risk of mortality 
and death outcome. 
Conclusion: laboratory tests are important to identifying kidney and heart failure and need to be used to improve clinical management 
of the hemodialysis treatment of people with chronic kidney disease in order to improve quality of life and life expectancy. 




Introducción: la hemodiálisis crónica tiene como objetivo reemplazar la función renal y proporciona una extensión de la esperanza 
de vida; sin embargo, en esta ocurren complicaciones que pueden llegar a ser graves e incluso fatales, por lo que conocerlas puede 
permitir hacer una mejor evaluación pronóstica y establecer un enfoque de intervención adecuado. Estos factores pueden ser 
identificados al realizar la anamnesis y la exploración física, y, con mayor precisión, mediante biomarcadores renales, cardíacos y 
pruebas de imagen. 
Objetivos: identificar los biomarcadores sanguíneos válidos para detectar insuficiencia cardíaca e insuficiencia renal asociada con 
enfermedad renal y hemodiálisis. 
Materiales y métodos: se realizó una revisión sistemática de la literatura en agosto de 2018 en las bases de datos Web Of Science, 
PubMed, Scopus, Cinahal, Cochrane, Science Direct y Lilacs. La pregunta guía fue ¿Cuáles son los biomarcadores de sangre 
utilizados para detectar la insuficiencia cardíaca y la insuficiencia renal? Se encontraron 537 publicaciones, de las cuales se excluyeron 
94 por estar repetidas, 383 después de leer títulos y resúmenes, 32 después de leer los textos completos y 10 en la síntesis 
cuantitativa y cualitativa. 
Resultados: Se incluyeron 18 documentos en la muestra final, los cuales presentan pruebas de laboratorio y de imagen, instrumentos 
para evaluar el riesgo de insuficiencia renal y cardíaca, así como el manejo clínico de la progresión de la insuficiencia renal y cardíaca. 
Todos los estudios correlacionaron el riesgo de mortalidad y resultado de la muerte. 
Conclusión: las pruebas de laboratorio son importantes para identificar la insuficiencia renal y cardíaca y deben utilizarse para 
mejorar el manejo clínico del tratamiento de hemodiálisis de personas con enfermedad renal crónica a fin de mejorar la calidad y la 
esperanza de vida. 
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hronic Kidney Disease (CKD) is characte- 
rized by the gradual loss of kidney function, 
culminating in end-stage renal failure. The 
more chronic the disease, the more likely the emer- 
gence of complications-e.g., anemia, electrolyte imba- 
lances, mineral disorders, atherosclerosis.1 These 
complications, in turn, trigger systemic changes, as is 
the case of cardiac function. Kidney disease and hemo- 
dialysis considerably increase changes in cardiac 
function, such as cardiomyopathy, diastolic dysfunction, 
congestive heart failure, coronary heart disease, and 
vascular changes.2,3 
 
Even with the advancements achieved in dialysis 
treatment, both acute and chronic events still involve 
hemodialysis (HD); that is, patients resume hemodia- 
lysis if there is some complication with the remaining 
modalities of treatment. HD is a procedure in which a 
machine filters a patient’s blood through a venous 
access to remove harmful residues in order to maintain 
a balance in electrolyte substances.4 HD is associated 
with high mortality, which is nine times higher among 
patients with CKD than in the general population. More 
than 50% of deaths are related to cardiac function. 
Sudden deaths are frequently caused by ventricular 
arrhythmias associated with HD due to sudden 
changes in potassium concentration or blood volume.2 
Complications happen and may be severe and fatal. 
Being aware of complications enables improved 
prognostic assessment and the employment of 
intervention strategies. Complications can be identified 
during anamnesis, physical assessment, or through 
kidney and cardiac biomarkers and imaging tests.5 
 
This study’s objective was to identify valid blood 
biomarkers to detect heart failure and kidney failure 
associated with kidney disease and hemodialysis. This 
type of research can be useful in identifying studies 
addressing the context of biomarkers that can be used 
in the care provided by multidisciplinary teams to 
individuals with CKD undergoing HD in order to 
improve the quality of care delivery and intervene in 
the progression of disease with the purpose of 




Systematic literature review intended to critically 
assess studies and collect scientific evidence of 
interventions used to qualify clinical practice.6 
Recommendations provided by the “Preferred Reporting 
Items for Systematic Reviews and Meta-Analyses” 
(Prisma) were used.7  Studies were searched in August 
2018 in the following databases: Web Of Science, 
PubMed, Scopus, Cinahal, Cochrane, Science Direct and 
Latin American and Caribbean Health Sciences 
Literature (LILACS). 
 
The descriptors from the Medical Subject Headings 
(MeSH) were used and the search was in accordance 
to the following: ((«heart failure»[MeSH Terms] OR 
«heart failure»[All Fields] OR «heart failures»[All 
Fields] OR «Cardiac Failure»[All Fields] OR «Cardiac 
Failures»[All Fields] OR «Heart Decompensation»[All 
Fields] OR «Myocardial Failure»[All Fields] OR 
«Myocardial Failures»[All Fields] OR «Myocardial 
Decompensation»[All Fields] OR «Cardio-Renal 
Syndrome»[All Fields] OR «Cardio- Renal Syndro- 
mes»[All Fields] OR «Renocardiac Syndrome»[All 
Fields] OR «Renocardiac Syndromes»[All Fields] OR 
«Cardiorenal Syndrome»[All Fields] OR «Cardiorenal 
Syndromes»[All Fields] OR «RenoCardiac Syndro- 
me»[All Fields] OR «Reno-Cardiac Syndromes»[All 
Fields] OR «renal insufficiency»[MeSH Terms] OR 
«renal insufficiency»[All Fields] OR «renal insuffi- 
ciencies»[All Fields] OR «renal failure»[All Fields] OR 
«renal failures»[All Fields] OR «Kidney Insuffi- 
ciency»[All Fields] OR «Kidney Insufficiencies»[All 
Fields] OR «Kidney Failure»[All Fields] OR «Kidney 
Failures»[All Fields] OR «Renal Failure»[All Fields] 
OR «Renal Failures»[All Fields]) AND («blood 
biomarkers»[All Fields] OR «blood biomarker»[All 
Fields] OR «blood markers»[All Fields] OR «blood 
marker»[All Fields] OR «Laboratory Markers»[All 
Fields] OR «Laboratory Marker»[All Fields] OR 
«Laboratory Biomarkers»[All Fields] OR «Laboratory 
Biomarker»[All Fields])) AND («Renal Dialysis» 
[Mesh:noexp] OR «renal dialysis»[All Fields] OR «Re- 
nal Dialyses»[All Fields] OR «hemodialysis»[All Fields] 
OR «haemodialysis»[All Fields] OR «hemodialyses» 
[All Fields] OR «haemodialyses»[All Fields] OR 
«Extracorporeal Dialyses»[All Fields] OR «Extracor- 
poreal Dialysis»[All Fields]). 
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Studies written in any period or language, 
answering the following question, were used: 
“What are the blood biomarkers used to detect 
heart and kidney failure?” A total of 537 
publications were identified, with 94 of these 
appearing more than once. The titles and 
abstracts of 443 publications were read and 
editorials, reflections, experience reports, 
monographs/dissertations/theses, and event 
abstracts, were excluded. Of these, 60 studies 
remained and their respective full texts were 
assessed. In this process, another 32 studies 
were excluded because they did not speci- 
fically address biomarkers of heart and kidney 
failure; that is, they addressed associations 
with other diseases in addition to kidney 
disease. Thus, 28 studies were taken into 
account in the qualitative and quantitative 
synthesis. Ten studies were excluded in this 
stage because they did not report the 
methodological model in such a way the study 
 
 
Figure 1. Flowchart of the different stages of systematic review. 
Source: own elaboration, 2019. 
could be reproduced. Eighteen studies remained in 
the final sample (Figure 1). 
 
Level of Evidence (LE) was assessed in accordance 
to Oxford Centre for Evidence- Based Medicine,8 
which rates the quality of evidence and strength of 
recommendations, to guide professional practice. 
Classification ranges from 1 (strong evidence, e.g., 
systematic reviews and metanalysis) to 5 (weak 
evidence, e.g., authority/expert opinion). The studies 
were also assessed using Strengthening the Reporting 
of Observational Studies in Epidemiology (Strobe), the 
objective of which is to assess information that needs 
to be included in the title, abstract, introduction, method, 
results and discussion of scientific observational 
studies. Eighteen of the 22 items assessed are common 
to cohort studies, case-control and sectional studies, 
while four items are specific to each of the three study 
designs. Consolidated Standards of Reporting Trials 
(Consort) was used to assess randomized trials, which 
is intended to clarify how a study was conducted, its 
validity and how applicable its conclusions are. For both 
instruments, studies that met the requirements of the 
Strobe’s 22 items and Consort, were classified as “M” 
studies (Meets the requirements); as “PM” (Partially 
Meets the requirements); or classified “DNM” (Does 
Not Meet the requirements).8-10 
Results 
 
The earliest studies were published in the 2000s 
and the countries of origin were the United States of 
America (n: 5), or were located in Europe (n: 7) or 
South America (n: 6). All the studies used a quantitative 
approach; most were cohort studies (Table 1). 
 
The blood biomarkers used in the studies to detect 
heart and kidney failure were identified and grouped 
according to biochemical, hematological, cardiac, 
cardiovascular, renal and inflammatory parameters that 





Laboratory and imaging tests used to identify 
kidney and heart failure 
 
Imaging tests included Doppler echocardiography, 
electrocardiogram, ultrasound imaging of the carotid 
artery and von Kossa’s method, used in histology to 
detect the presence of calcium in the radial artery. The 
studies also addressed previous diseases, sociodemo- 
graphic factors, diabetes mellitus, cardiovascular risk 
factors, coronary heart disease, stroke, atrial fibrillation, 
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Table 1. Characteristics of studies in terms of objective, design, and level of evidence. 
 
Reference Objective Design LE* Strobe Consort 




To assess survival and clinical changes associated with 













To apply a modified Framingham Heart Study approach 













To measure pregnancy-associated plasma protein A 












To determine the relationship between the common 
carotid artery intima-media thickness (CCA-IMT) and 
histologically assess calcification of radial artery in 

















To determine whether red blood cell distribution width 
(RBW) is associated with higher mortality rates  













To assess malnutrition and determine mortality  













To verify association between nutritional status, total 
plasma homocysteine levels, cardiovascular disease, and 



























To verify whether indications for HD initiation are 













To verify whether decreased kidney function is associated 













To assess sclerostin levels in patients with CKD and 
association between sclerostin levels, biochemical 













To verify whether the concentration of NT-proBNP is 













To study inflammatory markers before and 3-6 months 
after switching water purification system from 














To analyze the presence of valve calcification at the 
beginning of HD and its relationship to cardiovascular 













To verify whether left ventricular hypertrophy can explain 
association between education and cardiovascular 













The identify association between systemic inflammation 















To identify association between comorbidities, quantified 
according to Endstage Renal Disease Severity Index 





























Source: own elaboration, 2019. 
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Table 2. Details of laboratory tests to identify heart and kidney failure, 2019. 
 

























Assessment of platelet function 
Hormone Vitamin D 





























































Immune response protein Pentraxin 3 
Hormone Fibroblastic Growth Factor 23 
 
Source: own elaboration, 2019. 
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acute myocardial infarction, cancer, and acute lung 
edema, which were correlated with a risk of mortality 
and mortality. 
 
Laboratory tests include PAPP-A, which was 
measured in 78 patients for 60 months and correlated 
to HD routine tests. The median of PAPP-A levels 
was two times higher than the upper reference limit 
(140mIU/L), while values 14 times higher were found. 
Patients with CKD with cardiovascular events 
presented higher PAPP-A levels, indicating significant 
damage to endothelial cells and consequent increased 
risk of death. This same test was positively associated 
with serum sodium, potassium, and NT-proBNP.2,28,29 
 
RDW (iron-deficiency anemia marker), can be used 
as a marker of nutritional deficiency, inflammation and 
to predict mortality.30-32 One study addressing 109,675 
patients reports RDW percentages between 14.5% and 
17.5%. Association was found between RDW and 
mortality risk, that is, greater RDW levels were asso- 
ciated with an increased risk of death over time. The 
pathogenesis of high RDW levels is complex and some 
hypotheses include a inflammatory process that results 
from HD, which inhibits bone marrow function, changes 
iron metabolism, inhibits erythrocyte maturation and 
promotes oxidative stress leading to increased red blood 
cell heterogeneity.14,33,34 The nutritional state of a patient 
is directly related to hematological changes. One study 
assessed malnutrition based on three systems: Wolfson, 
Beberashvili and the International Society of Renal 
Nutrition and Metabolism (ISRNM). These systems 
serve to measure nutritional status and predict mortality. 
ISRNM predicted a fourfold higher risk of death. During 
the study, 21.5% of the participants died due to malnu- 
trition.15 Association between malnutrition, inflamma- 
tion, and comorbidities is one of the reasons for poor 
outcomes. In this context, one study sought to identify 
association between nutritional status, total plasma 
homocysteine (tHcy) levels, cardiovascular disease 
(CVD), and mortality among 124 patients undergoing 
HD for two years. The level of tHcy was higher among 
patients who died due to CVD (8.8%). A positive 
relationship was found between tHcy and albumin and 
creatinine.16,35 
 
Another laboratory text, sclerostin, was assessed in 
association with vascular disease markers and mortality 
in 140 patients. High sclerostin levels are correlated with 
inflammation markers, phosphate, fibroblast growth fac- 
tor, and arterial stiffness. Mortality was present 
regardless of age and inflammation parameters.18 
Cardiac events were assessed  in 211  patients, 
considering the cardiac biomarker creatine kinase-MB 
(CK-MB). The level of CK-MB was 1-2ng/mL, which 
does not exceed normal laboratory parameters. When 
it wascorrelated with other variables to predict 
cardiovascular events (such as age, sex, other chronic 
diseases), there was an increase of 17% in the 
discrimination of risk.27 Cardiovascular condition was 
assessed using platelet aggregation during the course of 
myocardial infarction (AMI) among patients with and 
without a CKD diagnosis. The study addressing 413 
patients with AMI hospitalized in a cardiac intensive care 
unit presented the following predictors: TFG below 60ml/ 
min/1.73m², comorbidities, medications, and inflammation 
markers and hemostasis. There was significant increase 
in platelet aggregation in the first three days of 
hospitalization, regardless of kidney function. This occurs 
more abruptly in patients with TFG below 60ml/min/ 
1.73m². Advanced age, elevated plasma fibrinogen and 
diabetes mellitus were associated with platelet 
aggregation.19,36,37 
 
One study’s objective was to identify the relationship 
between left ventricular hypertrophy (LVH), mortality 
and low education level.24 A total of 113 patients, assigned 
to two groups, participated in the study: up to three years 
of schooling and four or more years of schooling. A 
difference of 5.5 years was found regarding cardio- 
vascular mortality when comparing educational levels. 
LVH was associated with C-reactive protein, and 
cardiovascular mortality, as well as creatinine, systemic 
arterial hypertension, and different educational levels. 
LVH and risk of mortality was verified using NT- 
proBNP, cardiovascular failure and hypertrophy markers 
in a group of adult HD patients. In addition to the 
laboratory tests, echocardiograms were performed to 
measure ventricular mass. A highly significant 
relationship was found between NT- proBNP and LVH; 
the latter can be a useful biomarker of ventricular mass. 
A value greater than 10,000pg/ml can identify HD 
patients with an increased risk of death.21,38,39 
 
Cases of histological arterial calcification were also 
verified. The relationship between common carotid 
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artery, intima-media thickness (CCA-IMT) and 
histological calcification of radial artery in relation to 
clinical characteristics and laboratory markers, was 
verified.13 One study with 59 patients identified 
significant correlation between CCA-IMT with glucose 
blood tests, osteoprotegerin and pentraxian 3. 
Calcification of the radial artery was found in 34 
patients who also presented high CCA-IMT. Higher 
CCA-IMT was associated with more advanced 
calcifications. The presence of common carotid artery 
was a positive predictor of calcification of the radial 
artery, while calcification of the radial artery was a 
significant predictor of mortality. One study assessed 
valve calcification in 256 patients and associated it with 
demographic factors and cardiovascular risk.23,40 Acute 
myocardial infarction, stroke and death occurred in 26% 
of the patients; advanced age, coronary disease, and 
stroke predicted cardiovascular events. Association 
between systemic inflammation and left atrial dilatation 
was found in 58 patients through PCR measurement, 
interleukin 6 and Doppler echocardiography; high PCR 
was related to left atrial enlargement. Arteriosclerosis 
is a major complication of CKD and micro-inflammation 
is involved in atherogenesis, associated with uremia 
and dialysis water.25,41 Therefore, the study verifying 
dialysis water of two purification systems – deionization 
and reverse osmosis – addressing 47 patients, showed 
that uremic cases presented a decrease in PCR levels 
when water purified via reverse osmosis was used in 
dialysis, inducing fewer inflammatory processes and 
lower atherosclerosis. Sixteen of the participants died.22 
 
Methods to assess the risk of developing and 
progressing heart failureand kidney failure 
 
The methods to assess the risk of developing and 
progressing kidney and heart failure include: endstage 
renal disease severity index (ESRD-SI); Dialysis 
Outcomes and Practice Patterns Study (DOPPS); 
European Incident HD Patient Database (AROii); 
modified Framingham Heart Study approach; and risk 
of adverse events at the beginning of HD. These were 
correlated to indicators, laboratory and imaging tests, 
body mass index, smoking, glomerulonephritis, renal 
cysts, vascular access, HD complications, and death. 
 
One of the aspects analyzed included indication for 
HD initiation and mortality. Indications for initiating 
 
therapy included laboratory evidence, uremic 
symptoms, volume overload, and hypertension. Of 461 
patients, 183 (40%) died within 2.4 years, on average. 
After relating HD initiation to demographic variables, 
coexisting diseases, and glomerular filtration rate, the 
risk of mortality was 1.69 times greater.18 
 
The Endstage Renal Disease Severity Index 
(ESRD-SI) was used by one study to verify association 
between comorbidities, Kt/V, hematocrit, serum 
albumin, and mortality. The odds ratio of 40 patients 
for each ESRD-SI point was 10%; the factors with 
the greatest impact on mortality were diabetes mellitus, 
CVD and bone diseases.26,42,43 
 
Researchers applied a modified approach of the 
Framingham Heart Study to verify 1- and 2-year 
mortality rates. They used two European databases. A 
mortality rate of 13/100 patients/year was found. 
Increased age, low body mass index, CVD, cancer, 
venous access catheter, laboratory tests with abnormal 
results, were identified as predictors of mortality.12-44 
 
Nocturnal dialysis as an option for clinical 
management and control of abrupt progression 
of heart and kidney failure 
 
Nocturnal dialysis was presented in two studies 
correlating sociodemographic factors, comorbidities 
and preexisting chronic diseases, laboratory and 
imaging tests, and dialysis indicators, such as the 
number of sessions per week, length of sessions, ul- 
tra filtrate, and KtV. 
 
One study reports that improved HD results depend 
on the length of sessions. Thus, the researchers 
addressed 746 patients undergoing nocturnal HD and 
2,062 patients undergoing conventional HD. The 
mortality rate was lower (19%) among patients 
undergoing nocturnal HD compared to those under- 
going conventional HD (27%). Mortality decreased 25% 
among patients undergoing nocturnal HD when 
associated with age, body mass index, length of dialysis, 
increased interdialytic weight gain, albumin, hemoglobin, 
dialysis dosage, calcium, decreased pre-dialysis 
systemic blood pressure, ultrafiltrate rate, phosphorus, 
and leucocyte count.9,45-48 Therefore, the study reports 
that nocturnal HD has favorable clinical features, 
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laboratory biomarkers, and improved survival compared 
to conventional HD. Although one study addressing 87 
patients undergoing conventional HD (n: 42) and 
nocturnal HD (n: 45) does not report any correlation 
between different HD modalities and mortality rates, 
there was an increase in vascular access events, 
improved control of hyperphosphatemia and systemic 





This systematic literature review was intended to 
identify valid blood biomarkers to detect heart and 
kidney failure associated with kidney disease and 
hemodialysis treatment. This review shows that 
laboratory tests aid the identification of kidney and heart 
failure among HD patients with CKD. All the studies 
reported deaths associated with failure of these 
systems. The studies employed a quantitative approach 
and were conducted on three continents, in more than 
10 different countries. This review’s results present 
the most diverse possibilities of detecting kidney and 
heart failure and, for this reason, can support the 
planning of treatment of people with CKD with greater 
life expectancy and improved quality of life. 
Preventable complications that lead to kidney and heart 
disorders and death need to be predicted so that 
measures can be implemented. 
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